Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Maria Rosaria Valerio, Vittorio Gebbia, Ciccarese, Clivio, Laura Pizzuti, Vandone, Carlo Putzu, Vizzini, Giovanardi, Cagossi, Gambaro, Scognamiglio, Enrico De Conciliis, Montagna, Andrea Rocca, Vittorio Gebbia, Alfredo Butera, Carmela Mocerino, Cicchiello, MazzaToniolo, Ferzi, Orlando, Melegari, Ridolfi, Paolo Tralongo, Sarti, Paolo Marchetti, Andrea Fontana, Riva, Pellegrino, Ornella Garrone, Cazzaniga, Claudia De Angelis, Bordin, Bonfadini, Lorenzo Gianni, Generali, Taverniti, Galanti, Schintu, Fiorentini, Vizzini, Canicattì, Desorte, Fontana, Ferraù, Cappuccio, Turletti, Drudi, Valenza, Vandone, Putzu, Generali, Cretella, Generali, Elena Collovà, Antonino Grassadonia, Vallini, Antonio Febbraro, Saracchini, Maria Giuseppina Sarobba, Graziella Pinotti, Tinari, Saverio Cinieri, Valenza, Pietro Spadaro, Leonardi, Nicolini, Patrizia Vici, Ferdinando Riccardi, Domenico Amoroso, Cavanna, Maria Rosaria Valerio, Antonino Musolino, Valter Torri, Donati, Rossana Berardi, Daniele Santini, Drudi, Spagnoletti, Daniele Galanti

Risultato della ricerca: Articlepeer review

18 Citazioni (Scopus)

Abstract

Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-based ones (2011: 17.1% - 2016: 25.6%), whereas CAPE-based and MTX-based regimens remained stable. In the 1st-line setting, the highest ORR and DCR were observed for VRL-based regimens (single agent: 44% and 88%; combination: 36.7% and 82.4%, respectively). Assuming VRL-single agent as the referee treatment (median PFS: 7.2 months, 95% CI: 5.3–10.3), the longest median PFS were observed in VRL-combination regimens (9.5, 95%CI 88.8–11.3, HR = 0.72) and in CAPE-single agent (10.7, 95%CI 8.3–15.8, HR = 0.70). The VICTOR-6 study provides new data coming from the real-life setting, by adding new information regarding the use of mCHT as an option of treatment for MBC patients.
Lingua originaleEnglish
pagine (da-a)7-16
Numero di pagine10
RivistaTHE BREAST
Volume48
Stato di pubblicazionePublished - 2019

All Science Journal Classification (ASJC) codes

  • Surgery

Fingerprint Entra nei temi di ricerca di 'Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study'. Insieme formano una fingerprint unica.

Cita questo